A new hormonal therapy designed to treat uterine fibroids called relugolix has finished a Phase 3 study in Japan, and the results are positive. That’s welcome news for a SoftBank-backed company based in Basel, Switzerland called Roivant Sciences that’s separately dealing with much lousier news. Read More
Skip to content
Blancer.com Tutorials and projects
Freelance Projects, Design and Programming Tutorials